Fig. 2
Upregulated miR-23a-3p in in vivo-generated sorafenib resistant HCC cells. A Tumour growth of mice was recorded every 3 days. WT: vehicle group; R1–5: sorafenib-treated group. B Data are represented as the percentage of WT and R1-R5 cells, and each of the experiment was performed in triplicate. The IC50 values of sorafenib in tumour cells for 24 h were determined by MTT assay and were calculated by GraphPad Prism 7 with the equation of Y=Bottom+(Top-Bottom)/(1 + 10^((LogIC50X)*HillSlope)). Mean ± SD of IC50 was displayed and P-value of comparison between WT and sorafenib resistance group was shown. C The expression of miR-23a-3p in both parental and in vivo-generated sorafenib resistant cell lines. D and E Tumour growth in the re-injected mouse models. WT: mice with parental cells; R1/3/5: mice with in vivo-generated sorafenib resistant cells. F The expression of miR-23a-3p in the re-injected mouse model. The arrow indicates the start of sorafenib administration. One-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001